Mantle cell lymphoma

• PirtobrUtinib as frontline Therapy for elderly unfit/frail patient with MAntle cell lymphoma: a phase II study of the Fondazione Italiana Li … Pending
  2025-521666-10-01 4 "Mantle Cell Lymphoma"
• Study carried out at multiple centers to test Glofitamab in patients with mantle cell lymphoma who did not respond well to, or relapsed afte … Pending
  2025-523428-39-00 4 "Mantle Cell Lymphoma"
• A phase 3 study of orelabrutinib in combination with rituximab plus bendamustine (BR) compared with BR in subjects with treatment-naїve mant … Pending
  2025-524241-27-00 5 "Treatment-naїve mantle cell lymphoma (MCL)"
• Clinical trial to evaluate the efficacy and safety of pirtobrutinib in combination with rituximab in patients with indolent clinical forms o … Recruiting
  2024-511983-97-00 4 2025-09-29 "Adult patients with indolent MCL who have not previously rec"
• A research study to evaluate the safety and effectiveness of Zilovertamab Vedotin with or without Nemtabrutinib in adults with B-cell Malign … Recruiting
  2022-501374-19-00 4 2022-09-16 "Aggressive and Indolent B-cell Malignancies (mantle cell lym"
• A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adult Patients Wi … Recruiting
  2024-515593-27-00 5 2025-05-08 "relapsed or refractory mantle cell lymphoma (R/R MCL)"
• A first-in-human clinical study to assess safety and tolerability of genetically modified T-cells in ROR1 positive tumors Recruiting
  2024-512019-36-00 1 2025-04-09 "Adrenocortical carcinoma"
• A trial to learn if AZD0486 alone or with other anticancer drugs is safe and works in adults with certain blood cancers Recruiting
  2024-515034-33-00 9 2025-03-05 "Mantle Cell Lymphoma"
• A Phase I/IIa multicenter study evaluating the safety and efficacy of CAR20(NAP)-T in patients with relapsed/refractory B cell lymphoma (CAR … Recruiting
  2024-511844-18-00 7 2024-05-02 "Relapsed or refractory CD20+ diffuse large B-cell lymphoma, "
• A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies Recruiting
  2023-510541-25-00 1 2023-10-09 "Relapsed/Refractory B-cell Malignancies"
• A Dose Escalation and Expansion Study of BGB-16673 in Patients with B Cell Malignancies Recruiting
  2022-502157-33-00 7 2023-09-18 "B-Cell Malignancies"
• An early study to investigate a new medicine for Subjects with Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) Recruiting
  2024-515690-10-00 9 2019-05-10 "Follicular B-cell non-Hodgkin's lymphoma"
• Multicentric phase II trial to evaluate the efficacy and safety of Ibrutinib in combination with rituximab in patients with indolent clinica … Recruitment ended
  2024-512370-94-00 4 2024-06-13 "Mantle Cell Lymphoma"
• Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell … Recruitment ended
  2023-509908-15-00 10 2020-01-20 "Mantle Cell Lymphoma"
• A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previo … Recruitment ended
  2024-511747-25-00 4 2019-12-23 "B-cell non-Hodgkin lymphoma (NHL)"
• MB-CART19.1 r/r CD19+ BCM Recruitment ended
  2024-513334-38-00 1 2018-05-15 "Refractory/relapsed B-NHL"
• Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib Recruitment ended
  2023-507329-40-00 6 2017-09-28 "1. Follicular Lymphoma 2. Chronic Lymphocytic Leukemia 3. Wa"
• A phase 2 trial to study safety and efficacy of Capivasertib in patients with blood cancer where disease or cancer cell grows after a period … Ended
  2024-516386-36-00 4 2022-03-04 "Relapsed or Refractory B-cell Non-Hodgkin Lymphoma"
• Rituximab, bendamustine and cytarabine followed by venetoclax (V-RBAC) in high-risk elderly patients with mantle cell lymphoma (MCL) Ended
  2024-511533-35-00 4 2018-09-03 "Mantle Cell Lymphoma"
• A phase I/II trial of Obinutuzumab, ABT-199 (GDC-0199) plus Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma patients (OAsIs) Ended
  2024-516750-21-00 9 2015-10-14 "Patients with relapsed / refractory Mantle Cell Lymphoma"
• A Phase II study evaluating efficacy of KTE-X19 CAR-T cell therapy in Relapsed or Refractory Mantle-Cell Lymphoma achieving a partial respon … Expired
  2022-502907-31-00 4 2023-12-28 "Relapsed or Refractory Mantle-Cell Lymphoma"

Showing 1–21 of 21 trials